Featured Research

from universities, journals, and other organizations

Machine similar to dialysis removes cholesterol from blood

Date:
February 28, 2013
Source:
Loyola University Health System
Summary:
A treatment that's similar to kidney dialysis is removing cholesterol from the blood of patients who cannot control cholesterol through diet, exercise and medications.

Some patients are genetically prone to such dangerously high levels of cholesterol that no amount of diet, exercise and medications can reduce their cholesterol to safe levels.

So Loyola University Medical Center is offering a treatment called LDL apheresis, which is similar to kidney dialysis. Once every two weeks, a patient spends two to four hours connected to an apheresis unit that removes 70-to-80 percent of the patient's LDL (bad) cholesterol, then returns the blood to the body. The good HDL cholesterol is not removed.

Loyola is among a handful of centers in the Midwest -- and the only academic medical center in Chicago -- to offer LDL apheresis.

The Loyola LDL Apheresis Program is intended for patients who have been unable to control cholesterol with lifestyle changes and medications. They include patients with coronary heart disease who have LDL cholesterol greater than 200 mg/dL, and patients without coronary artery disease who have LDL levels greater than 300 mg/dL.

About 1 in 500 people have genetic abnormalities that cause LDL cholesterol levels three to five times as high as normal levels. The condition, called familial hypercholesterolemia, causes heart disease at a young age.

Familial hypercholesterolemia runs in Fran Tobias' family. Her father died of a heart attack in his early 40s, her mother had a heart attack at age 45, and two brothers died of heart disease. Tobias had her first heart attack at age 37, a second heart attack at age 45, a quintuple bypass surgery and eight stents.

Tobias, 56, who lives in Glen Ellyn, is successfully controlling her LDL by coming for apheresis treatments at Loyola every two weeks.

"This is literally a lifesaver for me," Tobias said. "If I were to stop, I probably would have another heart attack within 18 months to two years."

The Loyola LDL Apheresis Program is multidisciplinary. LDL apheresis is done under the guidance of medical specialists from Loyola's transfusion service, and patients have periodic clinical follow-ups with a lipidologist (cholesterol specialist). The program is directed by Binh An P. Phan, MD, and Phillip J. DeChristopher, MD, PhD. Phan is director of Loyola's Preventive Cardiology Program and DeChristopher is director of Transfusion Medicine and the Apheresis Center.

"The aim of the Loyola LDL Apheresis Program is to provide a multidisciplinary specialized service for the comprehensive evaluation and treatment of patients who require LDL apheresis," Phan said.


Story Source:

The above story is based on materials provided by Loyola University Health System. Note: Materials may be edited for content and length.


Cite This Page:

Loyola University Health System. "Machine similar to dialysis removes cholesterol from blood." ScienceDaily. ScienceDaily, 28 February 2013. <www.sciencedaily.com/releases/2013/02/130228171354.htm>.
Loyola University Health System. (2013, February 28). Machine similar to dialysis removes cholesterol from blood. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2013/02/130228171354.htm
Loyola University Health System. "Machine similar to dialysis removes cholesterol from blood." ScienceDaily. www.sciencedaily.com/releases/2013/02/130228171354.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins